A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oradoxel Monotherapy in Subjects With Advanced Malignancies
Latest Information Update: 06 Jan 2021
Price :
$35 *
At a glance
- Drugs Docetaxel/encequidar (Primary) ; HM 30181A (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 15 Oct 2019 Planned End Date changed from 1 Dec 2019 to 30 Mar 2020.
- 15 Oct 2019 Planned primary completion date changed from 1 Apr 2019 to 30 Mar 2020.
- 12 May 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.